Set up of a standby equity financing (PACEO®) to support the growth projects of BioAlliance Pharma
25 Jan, 2013
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, is setting up a standby equity financing (PACEO®) with Société Générale in accordance with the authorisation granted by the general meeting held on 31 May 2012.
This standby equity financing will enable, if needed, to reinforce the financial flexibility in order to support the acceleration of the development projects of BioAlliance Pharma and its external growth strategy.
Société Générale undertook to subscribe successive capital increases over the next 24 months, in tranches of up to 400 000 shares (i.e. 2.3% of the current capital) and up to 1,765,000 shares in aggregate (i.e. 9.9% of the current share capital).
The shares will be issued at a 5% discount to the volume weighted average price of the shares for the three trading days immediately preceding the relevant issue date. When issued, the shares are not intended to be kept by Société Générale, which aims at selling them in the market.
Potential impact of the standby equity financing (PACEO®) on a 1% stake in BioAlliance Pharma prior to the implementation of PACEO®: